BioCardia, Inc.: SATTERFIELD THOMAS A JR amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Satterfield Thomas A Jr amended his Schedule 13G stake filing for BioCardia, Inc., according to SEC accession 0001104659-26-125056. The filing updates his previously reported beneficial ownership position in the clinical-stage cardiovascular cell therapy developer. Schedule 13G amendments are typically filed by passive investors and signal changes in holdings that can affect shareholder concentration. The exact revised share count and ownership percentage were not disclosed in the filing headline. Investors will watch for further 13G or 13D activity to gauge institutional conviction in BioCardia.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Thomas A. Satterfield Jr., BioCardia, Inc.